The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | Disease genotypes that predict poor transplant outcomes in myelofibrosis
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses genotypes seen in patients with myelofibrosis (MF) that predict poor transplant outcomes and patient prognosis. Dr Gagelmann also discusses the importance of screening patients for these genotypes. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
